6 Depression Symptoms in Midlife Linked to Almost 50% Higher Dementia Risk

Health & LifestyleNews
396

Listen to article (english)

Translate to Spanish or other 102 languages!

In 2021, about 57 million people globally were living with dementia — an umbrella term for neurological conditions that impact a person’s cognitive skills and memory, such as Alzheimer’s disease and vascular dementia. Image for illustration purposes
In 2021, about 57 million people globally were living with dementia — an umbrella term for neurological conditions that impact a person’s cognitive skills and memory, such as Alzheimer’s disease and vascular dementia. Image for illustration purposes

Medical News Today

- Advertisement -

In 2021, about 57 million people globally were living with dementia — an umbrella term for neurological conditions that impact a person’s cognitive skills and memory, such as Alzheimer’s disease and vascular dementia.

While researchers are still unclear what exactly causes dementia, they have identified a number of risk factors including genetics, environmental factors, certain lifestyle choices, and specific health conditions. 

One such condition is depression, especially during midlife.

- Advertisement -

Follow the link below to read the full story:

https://www.medicalnewstoday.com/articles/6-depression-symptoms-in-midlife-linked-to-almost-50-higher-dementia-risk

Information source: https://www.medicalnewstoday.com

- Advertisement -
- Advertisement -

Latest news

- Advertisement -
Previous article
From Patient to Hero: Isaac Garza Delivers 2,089 Smiles This Holiday Season
Next article
AMA Offers 10 Health Recommendations for the New Year

More Articles

STHS Dedicating Latest “South Texas Healthy Living” Episode to Arthritis Education, July 26th

More than 58 million U.S. adults are living with doctor-diagnosed arthritis, according to the Centers for Disease Control and Prevention (CDC), making it the nation’s leading cause of disability.

No More Needles: FDA Approves First Daily Pill to Replace Injectable Cholesterol Drugs

The U.S. Food and Drug Administration approved Lipfendra (enlicitide), the first oral inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9), as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C), or “bad” cholesterol, in adults with hypercholesterolemia, including those with heterozygous familial hypercholesterolemia (HeFH). Image source: Merck.com.

Physicians Warn of Rising ER Visits Linked to E-Bikes and Scooters

Mega Doctor News CLEVELAND CLINIC - As electric bikes and scooters grow in...

STHS Heart Ranks Among Nation’s Top Hospitals for Heart Attack Care

Every year, more than 800,000 people in the United States suffer a heart attack, according to the Centers for Disease Control and Prevention, an event that occurs approximately every 40 seconds.
- Advertisement -